OXFORD - Genzyme General is linking up with Pharming Group N.V. as GENZ pursues its mission to develop medicines to treat lysosomal storage disorders. GENZ is establishing a joint venture with PHAR to further develop and commercialize the Dutch company's lead product, human alpha glucosidase (hAG), as a treatment for Pompe's disease, an inherited deficiency of acid maltase that disables muscles.

This is PHAR's first corporate deal since completing its IPO on EASDAQ earlier this month (see BioCentury, July 6).